SEGMENT REPORTING

3 Months Ended

Mar. 31, 2014

Notes to Financial Statements

SEGMENT REPORTING

5. SEGMENT REPORTING

The Company is comprised of two reportable segments, Core Companion Animal Health ("CCA") and Other Vaccines, Pharmaceuticals and Products ("OVP"). The CCA segment includes blood testing instruments and supplies, digital imaging products, software and services, and single use products and services such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. These products are sold directly by the Company as well as through other distribution relationships. CCA segment products manufactured at the Des Moines, Iowa production facility included in our OVP segment's assets are transferred at cost and are not recorded as revenue for our OVP segment. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle, but also for other animals including small mammals and horses. All OVP products are sold by third parties under third-party labels.

Summarized financial information concerning the Company's reportable segments is shown in the following table (in thousands):

	Core Companion Animal Health				Other Vaccines, Pharmaceuticals and Products	Total
Three Months Ended March 31, 2013:
Total revenue	$	15,649		$	3,330	$	18,979
Operating income (loss)		(1,093	)		411		(682	)
Interest expense		51			6		57
Total assets		78,285			11,279		89,564
Net assets		41,034			7,023		48,057
Capital expenditures		309			8		317
Depreciation and amortization		279			195		474
Three Months Ended March 31, 2014:
Total revenue	$	17,366		$	3,427	$	20,793
Operating income (loss)		(308	)		207		(101		)
Interest expense		37			13		50
Total assets		80,839			13,187		94,026
Net assets		41,484			4,606		46,090
Capital expenditures		1,211			106		1,317
Depreciation and amortization		543			186		729